InMed Provides Update on INM-405 Development

- October 17th, 2017

InMed Pharmaceuticals shared some pre0-clinical results from the development of INM-405 for the treatment of pain.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) shared some pre0-clinical results from the development of INM-405 for the treatment of pain.
As quoted in the press release:

Results from these studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects, and may be a more desirable strategy than systemic pain-relief administration. Previously, InMed reported (NR August 20, 2015) the expression of both CB1 and CB2 receptors in trigeminal ganglion neurons innervating the masseter muscle, providing evidence that these receptors can be targets for craniofacial muscle pain.  CB1 and CB2 receptors are primary targets in the human body for cannabinoid drugs.
There is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed continues to research the potential of non-THC cannabinoids to treat pain using a topical formulation.

Click here to read the full press release.


Leave a Reply